Vanda Pharmaceuticals (VNDA) Non-Current Deffered Revenue (2010 - 2014)

Vanda Pharmaceuticals has disclosed Non-Current Deffered Revenue across 5 years of filings, most recently posting $3.1 million for Q4 2014.

• Non-Current Deffered Revenue for Q4 2014 came in at $3.1 million, down 95.12% year-over-year; the trailing twelve-month figure through Dec 2014 was $3.1 million (down 95.12% YoY), and the FY2014 annual result was $3.1 million, down 95.12% from the prior year.
• Non-Current Deffered Revenue came in at $3.1 million for Q4 2014 at Vanda Pharmaceuticals, up from $2.9 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $130.6 million in Q2 2011 to a low of $490000.0 in Q4 2010.
• The 5-year median for Non-Current Deffered Revenue is $27.4 million (2014), against an average of $48.7 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 23790.61% in 2011 and tumbled 98.02% in 2012, its largest moves.
• Vanda Pharmaceuticals' Non-Current Deffered Revenue stood at $490000.0 in 2010, then surged by 23790.61% to $117.1 million in 2011, then slipped by 22.88% to $90.3 million in 2012, then slipped by 29.67% to $63.5 million in 2013, then slumped by 95.12% to $3.1 million in 2014.
• The last three Non-Current Deffered Revenue figures came in at $3.1 million (Q4 2014), $2.9 million (Q3 2014), and $2.9 million (Q2 2014), per Business Quant data.